We're proud to share that our portfolio company Azalea Vision has completed the first closing of its Series A round, raising €9 million.
Founded in 2021 as a spin-off from imec and Ghent University, Azalea Vision is developing the first medical-grade smart lens to help patients with fluctuating or irregular vision conditions such as presbyopia, keratoconus, and photophobia.
The technology intelligently enhances sight by sensing, adapting to light and movement, and interacting in real time. Its potential extends beyond vision correction to applications such as diagnostics, biosensing, and ocular drug delivery.
This Series A funding will support Azalea Vision’s next milestone: a first-in-human pilot clinical trial, essential for demonstrating the safety and performance of its breakthrough technology. This trial will pave the way for IDE approval by the FDA and, ultimately, commercialization.
You can read the full press release on Business Wire.